SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals zooms on getting EIR from USFDA for Karakhadi facility

08 Jul 2016 Evaluate

Alembic Pharmaceuticals is currently trading at Rs 601.05, up by 20.95 points or 3.61% from its previous closing of Rs. 580.10 on the BSE.

The scrip opened at Rs. 582.30 and has touched a high and low of Rs 624.00 and Rs. 576.30 respectively. So far 85455 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 791.70 on 15-Jul-2015 and a 52 week low of Rs. 514.35 on 05-Feb-2016.

Last one week high and low of the scrip stood at Rs 624.00 and Rs 573.05 respectively. The current market cap of the company is Rs 11328.86 crore.

The promoters holding in the company stood at 74.13%, while Institutions and Non-Institutions held 13.54% and 12.33% respectively.

Alembic Pharmaceuticals has received Establishment Inspection Report (EIR) from US Food & Drug Administration (USFDA). The regulator had carried out the inspection at the Company's Karakhadi API Plant III in April, 2015.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.

Alembic Pharma Share Price

759.00 -25.95 (-3.31%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×